CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism

AJP Gastrointestinal and Liver Physiology (Impact Factor: 3.8). 06/2013; 305(3). DOI: 10.1152/ajpgi.00102.2013
Source: PubMed


CTRP3 is a secreted plasma protein of the C1q family that helps regulate hepatic gluconeogenesis and is down-regulated in a diet-induced obese state. However, the role of CTRP3 in regulating lipid metabolism has not been established. Here, we used a transgenic mouse model to address the potential function of CTRP3 in ameliorating high-fat diet-induced metabolic stress. Both transgenic and wild-type mice fed a high-fat diet showed similar body weight gain, food intake, and energy expenditure. Despite similar adiposity to wild-type mice upon diet-induced obesity (DIO), CTRP3 transgenic mice were strikingly resistant to the development of hepatic steatosis, had reduced serum TNF-α levels, and demonstrated a modest improvement in systemic insulin sensitivity. Additionally, reduced hepatic triglyceride levels were due to decreased expression of enzymes (GPAT, AGPAT, and DGAT) involved in triglyceride synthesis. Importantly, short-term daily administration of recombinant CTRP3 to DIO mice for 5 days was sufficient to improve the fatty liver phenotype, evident as reduced hepatic triglyceride content and expression of triglyceride synthesis genes. Consistent with a direct effect on liver cells, recombinant CTRP3 treatment reduced fatty acid synthesis and neutral lipid accumulation in cultured rat H4IIE hepatocytes. Together, these results establish a novel role for CTRP3 hormone in regulating hepatic lipid metabolism and highlight its protective function and therapeutic potential in attenuating hepatic steatosis.

15 Reads
  • Source
    • "Studies in vivo indicated that a modest 3-fold elevation of plasma CTRP3 levels by recombinant protein administration in normal and insulin resistant ob/ob mice is sufficient to lower glucose levels which may be mediated by up-regulating the protein kinase B (PKB) and inhibiting the expression of the gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase in liver [5]. A recent study showed that CTRP3 attenuated diet-induced hepatic steatosis by regulating triglyceride metabolism [6], indicating that CTRP3 may be an important regulator of lipid metabolism as well as glucose metabolism. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to investigate the expression of C1q/TNF-related protein-3 (CTRP3) in rats at different pathogenic stages of type 2 diabetes mellitus (T2DM) and the impacts of glucagon-like peptide-1 (GLP-1) receptor agonist on it. Male wistar rats were fed with high-fat diet for 10 weeks to induce insulin resistance (IR) and then were given low-dose streptozotocin (STZ) intraperitoneal injection to induce T2DM. Exendin-4 (Ex-4), a GLP-1 receptor agonist, was subcutaneous injected to the IR rats and T2DM rats for 4 weeks. The expression of CTRP3 mRNA and protein in epididymis adipose tissue of rats at the stage of IR was lower significantly than that of normal control (NC) rats and decreased more when they were at the stage of overt T2DM (all P < 0.05 or P < 0.01). After the treatment with Ex-4, the mRNA and protein expressions of CTRP3 were increased by 15.5% (P < 0.01) and 14.8% (P < 0.05), respectively, in IR rats and increased by 20.6% (P < 0.01) and 16.5% (P < 0.05), respectively, in T2DM rats. Overall, this study found that the expression of CTRP3 in visceral adipose tissue was progressively decreased in a T2DM rat model from the pathogenic stage of IR to overt diabetes, while Ex-4 treatment increased its expression in such animals.
    Journal of Diabetes Research 08/2014; 2014:398518. DOI:10.1155/2014/398518 · 2.16 Impact Factor
  • Source
    • "While no differences in body weight, energy expenditure, and glucose tolerance are observed between CTRP3 Tg and WT mice, the transgenic animals are strikingly resistant to the development of fatty liver (steatosis) in response to high-fat feeding [11]. Overexpressing CTRP3 in mice suppresses the expression of genes (Gpat, Agpat, Dgat) involved in triglyceride synthesis, leading to decreased triglyceride accumulation in the liver of the Tg animals [11]. Of the CTRP Tg mouse models described to date, the most dramatic and striking phenotypes are observed in mice overexpressing CTRP9 [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: CTRP2 is a secreted plasma protein of the C1q family that enhances glycogen deposition and fat oxidation in cultured myotubes. Its in vivo metabolic function, however, has not been established. We show here that acute and chronic metabolic perturbations induced by fasting or high-fat feeding up-regulated the mRNA expression of Ctrp2 in white adipose tissue without affecting its circulating plasma levels. We generated a transgenic mouse model with elevated circulating levels of CTRP2 to determine its metabolic function in vivo. When fed a low-fat diet, wild-type and CTRP2 transgenic mice exhibited no metabolic phenotypes. When challenged with a high-fat diet to induce obesity, wild-type and CTRP2 transgenic mice had similar weight gain, adiposity, food intake, metabolic rate, and energy expenditure. Fasting serum lipid and adipokine profiles were also similar between the two groups of mice. However, while glucose and insulin levels in the fasted state were comparable between wild-type and CTRP2 transgenic mice, insulin levels in the fed state were consistently lower in transgenic mice. Notably, CTRP2 transgenic mice had improved insulin tolerance and a greater capacity to handle acute lipid challenge relative to littermate controls. Our results highlight, for the first time, the in vivo role of CTRP2 in modulating whole-body metabolism.
    PLoS ONE 02/2014; 9(2):e88535. DOI:10.1371/journal.pone.0088535 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CTRP9 is a secreted multimeric protein of the C1q family and the closest paralog of the insulin-sensitizing adipokine, adiponectin. The metabolic function of this adipose tissue-derived plasma protein remains largely unknown. Here, we show that the circulating levels of CTRP9 are downregulated in diet-induced obese mice and upregulated upon refeeding. Over-expressing CTRP9 resulted in lean mice that dramatically resisted weight gain induced by a high-fat diet, largely through decreased food intake and increased basal metabolism. Enhanced fat oxidation in CTRP9 transgenic mice resulted from increases in skeletal muscle mitochondrial content, expression of enzymes involved in fatty acid oxidation (LCAD and MCAD), and chronic AMPK activation. Hepatic and skeletal muscle triglyceride levels were substantially decreased in transgenic mice. Consequently, CTRP9 transgenic mice had a greatly improved metabolic profile with markedly reduced fasting insulin and glucose levels. The high-fat diet-induced obesity, insulin resistance, and hepatic steatosis observed in wild-type mice were prevented in transgenic mice. Consistent with the in vivo data, recombinant protein significantly enhanced fat oxidation in L6 myotubes via AMPK activation and reduced lipid accumulation in H4IIE hepatocytes. Collectively, these data establish CTRP9 as a novel metabolic regulator and a new component of the metabolic network that links adipose tissue to lipid metabolism in skeletal muscle and liver.
    AJP Regulatory Integrative and Comparative Physiology 07/2013; 305(5). DOI:10.1152/ajpregu.00110.2013 · 3.11 Impact Factor
Show more